World-First Genetic Immunotherapy Trial Targets Pancreatic Cancer

Immunotherapy /

Doctors have performed a world-first genetic immunotherapy treatment for pancreatic cancer, adapting immune cell techniques usually used in blood cancers to treat a solid tumor. The process involves removing a patient’s T-cells, genetically modifying them to recognize specific features of pancreatic cancer cells, and then reinfusing them back into the body so they can target and […]

World-First Genetic Immunotherapy Trial Targets Pancreatic Cancer Read More »

Pelareorep Combo Shows Extended Survival Benefit in RAS-Mutant Metastatic Colorectal Cancer

Clinical Trails /

Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, added to standard FOLFIRI and bevacizumab may significantly improve outcomes in RAS-mutant, microsatellite-stable metastatic colorectal cancer. The combination performed much better than historical results for second-line treatment. Median duration of response reached 19.5 months compared with about 4 to

Pelareorep Combo Shows Extended Survival Benefit in RAS-Mutant Metastatic Colorectal Cancer Read More »

Single-Infusion CAR T Therapy Achieves 100% MRD Negativity in High-Risk Smoldering Myeloma

Clinical Trails /

The Phase 2 CAR-PRISM trial shows striking results for high-risk smoldering multiple myeloma using the CAR T-cell therapy ciltacabtagene autoleucel (Carvykti). A single infusion led to 100% of patients achieving minimal residual disease (MRD) negativity at a very deep level. At a median follow-up of 15.3 months, all patients achieved complete or stringent complete responses, with

Single-Infusion CAR T Therapy Achieves 100% MRD Negativity in High-Risk Smoldering Myeloma Read More »

Ozekibart Shows Promising Response Rates in Relapsed Ewing Sarcoma

Clinical Trails /

Early clinical data suggest that ozekibart (INBRX-109), a DR5 agonist, could offer a new treatment option for Ewing sarcoma, a rare and aggressive cancer. In a Phase 1 study, ozekibart was combined with standard chemotherapy (temozolomide and irinotecan) in patients with relapsed or refractory disease. Among 31 patients, the response rate reached 64.5%, much higher

Ozekibart Shows Promising Response Rates in Relapsed Ewing Sarcoma Read More »

Pelareorep Combo Shows Promising Survival Gains in KRAS-Mutant Metastatic Colorectal Cancer

Treatment /

Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, combined with bevacizumab and FOLFIRI, may significantly improve outcomes in KRAS-mutant metastatic colorectal cancer. Patients receiving the combination had a response rate of 33% and a median duration of response of 19.5 months, far better than typical results with

Pelareorep Combo Shows Promising Survival Gains in KRAS-Mutant Metastatic Colorectal Cancer Read More »

FDA Approves Vepdegestrant with Liquid Biopsy Test for ESR1-Mutated Breast Cancer

Diagnostics /

On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. At the same time, the Guardant360 CDx was approved as a companion diagnostic to detect these mutations using a simple blood test. The approval is based on the Phase 3 VERITAC-2 trial, which compared vepdegestrant

FDA Approves Vepdegestrant with Liquid Biopsy Test for ESR1-Mutated Breast Cancer Read More »

Duvelisib Shows Strong Activity in Relapsed Peripheral T-Cell Lymphoma

Clinical Trails /

The Phase 2 PRIMO trial found that duvelisib (Copiktra), an oral drug targeting PI3K-δ and PI3K-γ, can work as a single treatment for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In the study of 123 heavily pretreated patients, nearly half responded to the drug. The overall response rate was 48%, with about one-third

Duvelisib Shows Strong Activity in Relapsed Peripheral T-Cell Lymphoma Read More »

Study Finds Metabolic Weak Spot That Could Boost Cancer Treatment

Research Advances /

Researchers have found that disrupting a metabolic process called lipoylation can make cancer cells more vulnerable to certain treatments. The study shows that the enzyme LIPT1 links cell metabolism to DNA stability. When LIPT1 is blocked, a substance called 2-hydroxyglutarate builds up, causing DNA to become overly compacted. This slows DNA copying and leads to

Study Finds Metabolic Weak Spot That Could Boost Cancer Treatment Read More »

New Blood Test Using Nanotechnology Detects Pancreatic Cancer with 97% Accuracy

Diagnostics /

Scientists have developed a new blood test that uses nanotechnology and electrical signals to detect pancreatic cancer with high accuracy. Led by Stuart Ibsen, the test uses a microchip that applies a small electric charge to blood samples to capture tumor-derived nanoparticles. These particles are then labeled to identify cancer-specific biomarkers. In a blinded study, the

New Blood Test Using Nanotechnology Detects Pancreatic Cancer with 97% Accuracy Read More »

FDA Grants Expanded Access to Daraxonrasib After Promising Pancreatic Cancer Trial Results

Drug Approvals /

The U.S. Food and Drug Administration has authorized an expanded access program for daraxonrasib, an experimental treatment for patients with previously treated metastatic pancreatic cancer. The decision follows strong results from the Phase 3 RASolute 302 trial. The study showed that daraxonrasib significantly improved survival compared with standard chemotherapy. The drug reduced the risk of

FDA Grants Expanded Access to Daraxonrasib After Promising Pancreatic Cancer Trial Results Read More »